Aprotinin and Heparin Monitoring During Cardiopulmonary Bypass
暂无分享,去创建一个
[1] M. Yacoub,et al. Aprotinin and cardiac surgery. , 1991, BMJ.
[2] J. Levy,et al. Increased anticoagulation during cardiopulmonary bypass by aprotinin. , 1991, The Journal of thoracic and cardiovascular surgery.
[3] W. van Oeveren,et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. , 1990, The Journal of thoracic and cardiovascular surgery.
[4] I. Yada,et al. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. , 1989, Journal of cardiothoracic anesthesia.
[5] K. M. Taylor,et al. EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY , 1987, The Lancet.
[6] B. Bull,et al. Platelet Involvement in the Activated Coagulation Time of Heparinized Blood , 1984, Anesthesia and analgesia.
[7] J. A. Cohen. Activated Coagulation Time Method for Control of Heparin is Reliable during Cardiopulmonary Bypass , 1984, Anesthesiology.
[8] H. Fritz,et al. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. , 1983, Arzneimittel-Forschung.
[9] C. Kisker,et al. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. , 1978, The Annals of thoracic surgery.